|
|
|
| Therapeutic Effect of Thalidomide on Rheumatoid Arthritis and Its Effect on Serum Levels of Cys-C and Vascular Endothelial Growth Factor |
| CHEN Guanya, XIE Ye |
| Xianning Central Hospital, Hubei Xianning 437000, China |
|
|
|
|
Abstract Objective: To study the therapeutic effect of thalidomide on rheumatoid arthritis and its effect on serum levels of Cystatin C (Cys-C)and vascular endothelial growth factor (VEGF). Methods: 96 rheumatoid arthritis patients who received therapy from March 2017 to February 2018 in our hospital were selected as research objects. According to random number table method,those patients were divided into the observation group (n=50) and the control group (n=46). The control group was treated with methotrexate, and the observation group was treated with both methotrexate and thalidomide. Then the therapeutic efficacy, improvement of clinical symptoms, levels of related indicators, bone metabolism indicators, serum levels of Cys-C and vascular endothelial growth factor of two groups after treatment were compared. Results:After treatment, the total effective rate of observation group was significantly higher than that of control group[96.00%(48/50)vs76.08%(35/46)](P＜0.05). Joint tenderness index, joint swelling index and morning stiffness time were significantly lower than those in the control group[(1.71±0.50)vs (5.90±1.42),(1.42±0.32)vs (5.61±1.27),(8.03±1.20)min vs (21.74±5.40)min](P＜0.05). The levels of ESR and CRP were significantly lower than those of the control group[(3.05±0.92)mm/h vs (17.43±4.13)mm/h,(4.02±0.67)mg/L vs (12.01±1.35)mg/L](P＜0.05). N-MID and T-PINP were significantly higher than those in the control group[(20.13±3.72)mg/mL vs (14.63±2.70)mg/mL,(47.30±6.51)mg/mL vs (38.46±5.17)mg/mL](P＜0.05). The level of beta-CTX was significantly lower than that of the control group[(0.46±0.10)pg/mL vs (0.72±0.16)pg/mL](P＜0.05). Cys-C and vascular endothelial growth factor levels were significantly lower than those in the control group[(0.67±0.12)mg/L vs (1.35±0.30)mg/L,(32.76±7.42)μmol/L vs(50.95±10.64)μmol/L](P＜0.05).Conclusion:Thalidomide can improve the clinical symptoms and bone metabolism of patients with rheumatoid arthritis. It can regulate immunity, reduce the levels of Cys-C and VEGF. It has less adverse reactions and is safe and reliable.
|
|
|
|
|
|
[1] Coras R,Narasimhan R,Guma M.Liquid biopsies to guide therapeutic decisions in rheumatoid arthritis.[J].Clinical Chemistry&Laboratory Medicine,2018,13(5):1~10.
[2] Hunt,Nicole,Talabi,Mehret Birru.Family planning and rheumatoid arthritis[J].Current Rheumatology Reports,2019,21(5):16.
[3] 刘敏,王培蓉,马方伟,等.雷公藤多苷治疗类风湿关节炎的临床观察及对血清VEGF、VEGFR2表达水平的影响研究[J].陕西中医,2016,37(1):72~74.
[4] Gulati M,Farah,Ziad,Mouyis,Maria.Clinical features of rheumatoid arthritis[J].Medicine,2018,46(4):211~215.
[5] 宋明霞.类风湿关节炎治疗现状[J].中医药临床杂志,2017,29(8):1200~1204.
[6] 孟鹏飞.沙利度胺联合来氟米特与甲氨蝶呤治疗类风湿关节炎的疗效观察[J].大家健康(学术版),2016,10(11):73~74.
[7] Masakazu M.The Association of anti-aminoacyl-transfer ribonucleic acid synthetase antibodies in patients with rheumatoid arthritis and interstitial lung disease[J].Archives of Rheumatology,2018,33(1):26~32.
[8] 陈永,管剑龙.沙利度胺在临床风湿性疾病中的应用[J].复旦学报(医学版),2016,43(5):620~624.
[9] Wang Xueping,Cheng Qianyao,Gu Mingming,et al.Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis:a meta-analysis[J].Clinical Rheumatology,2019,38(7):1841~1849.
[10] 陈莉.沙利度胺联合来氟米特与甲氨蝶呤治疗类风湿关节炎的疗效观察[J].临床医药文献电子杂志,2017,4(5):932. |
|
|
|
2020, Vol. 26 
